Comparing two drugs for liver graft-versus-host disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12 years or older.
- Had a stem cell transplant from a donor (allogeneic).
- Have liver problems caused by graft-versus-host disease (GVHD), such as high bilirubin or liver enzymes.
- Be able to take pills by mouth.
- Have a life expectancy of at least 6 months.
- Have adequate organ function, including blood counts and kidney function (creatinine clearance of at least 30 mL/min).
- Be either in Group 1 (liver GVHD did not improve after at least 4 weeks of steroids) or Group 2 (liver GVHD developed or worsened while taking ruxolitinib or belumosudil for other GVHD, and you have not taken the other study drug before).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (belumosudil and ruxolitinib) for people with chronic graft-versus-host disease (cGvHD) that has not improved with steroid treatment. The goal is to see if this combination can better control the condition.
This trial tests a new combination of two drugs (an IL6-receptor inhibitor plus belumosudil) for people with chronic graft-versus-host disease that hasn't improved with belumosudil alone. It aims to see if this combination is safe and helpful for controlling cGVHD symptoms.
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This study tests a new medicine called belumosudil for people who have chronic graft-versus-host disease (cGVHD) that has not improved with at least two earlier treatments. It compares belumosudil to other available treatments to see which works better and is safer.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.